GENE EDITING MARKET Size and trends

Gene Editing Market Size and Trends

The Global Gene Editing Market is estimated to be valued at USD 4.80 Bn in 2025 and is expected to reach USD 9.51 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2025 to 2032.

Key Takeaways of the Gene Editing Market:

• By product, the kits segment is expected to contribute the highest share of the market with 42.1% in 2025.
• By technology, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) segment is expected to contribute the highest share of the market with 34.2% in 2025.
• By application, the cell line engineering segment is expected to contribute the highest share of the market with 41.2% in 2025.
• North America is projected to top the global market with 32.3% share in 2025, followed by Asia Pacific with 26.6% share in 2025.

Market Overview:

The gene editing market is expected to witness high growth due to increasing investments from both private and public sectors. There is a rising focus on developing therapies for various genetic diseases along with their commercial applications in the biotechnology and agriculture industries worldwide. Advanced technologies, such as CRISPR/Cas9, have provided opportunities to manipulate DNA with high precision. Growing application areas such as genetic engineering in crops is another factor supporting the use of gene editing. However, strict regulations for their clinical usage could pose a challenge for market growth to some extent. If ongoing clinical trials demonstrate success and safety, it will help accelerate the product acceptance and commercialization of gene editing technologies.

To learn more about this report, Request sample copy

Top Strategies Followed by Global Gene Editing Market Players:

• Leading companies in the gene editing market prioritize substantial investments in research and development to drive innovation and maintain a competitive edge. For instance, Vertex Pharmaceuticals has demonstrated a robust commitment to advancing gene editing therapies, with significant investments in this area.
  • Forming strategic alliances is essential for leading players to enhance their technological prowess and market presence. For instance, in November 2020, Precision BioSciences partnered with Eli Lilly to utilize its ARCUS genome editing platform for developing therapies targeting genetic disorders, including Duchenne muscular dystrophy.
• Mid-level players in the gene editing market adopt cost-effective strategies to gain market share. They focus on delivering quality gene editing kits, reagents and services at competitive prices to attract price-sensitive customers including research institutes and scientists. Alliances with major industry players are crucial for solidifying market presence.
  • For instance, in September 2023, Regeneron Pharmaceuticals completed its acquisition of Decibel Therapeutics, enhancing its gene therapy programs and expanding its capabilities in the gene editing space. Such partnerships allow companies to leverage each other's strengths and resources.
• Smaller companies often carve out niches by focusing on specific market segments or developing unique gene editing technologies. For example, Locus Biosciences specializes in CRISPR-enhanced bacteriophages to target and eliminate harmful bacteria, addressing a specific need within the biotech industry.

Emerging Startups - Gene Editing Industry Ecosystem

• Innovative startups are exploring advanced technologies to advance the gene editing field. Companies like KSQ Therapeutics are developing AI-guided CRISPR systems that could automate the design of gene therapies. Khloris Biosciences uses hyper editing to make multiple simultaneous changes to the genome, increasing efficiency. Such technologies may transform clinical research and drug discovery processes in the future.
• Companies like Pairwise are focusing on sustainability by developing gene-edited crops that require fewer resources. Pairwise has introduced gene-edited mustard greens with a milder flavor, aiming to increase consumer acceptance and promote healthier eating habits.
• Partnerships between startups and established companies or research institutions are common strategies to drive innovation. For instance, in June 2024, Roche partnered with Ascidian Therapeutics to develop gene therapies targeting neurological diseases, combining resources to advance RNA exon editing technologies.

Key Developments:

• In December 2024, Editas Medicine, a gene editing company, announced a strategic shift to focus entirely on in vivo gene editing, optimizing its cost structure and extending its cash runway into Q2 2027. The company aims to achieve in vivo human proof of concept within two years.
• In January 2024, Danaher Corporation, a global leader in life sciences and diagnostics, partnered with the Innovative Genomics Institute (IGI) to advance CRISPR-based therapies for rare genetic disorders by combining Danaher’s technological capabilities with IGI’s academic expertise.
• In November 2023, Cellectis, a pioneer in gene-editing solutions, and AstraZeneca, a global biopharmaceutical company, announced a collaboration to accelerate therapeutic advancements in oncology and immunology
• In July 2023, Sangamo Therapeutics, a leader in genomic medicines, joined forces with Chroma Medicine, a biotechnology company, to develop epigenetic therapies using Sangamo's Zinc Finger Proteins (ZFPs). Chroma will explore ZFPs for targets beyond the central nervous system with potential licensing opportunities.
• In May 2023, researchers at the Lewis Katz School of Medicine at the University of Nebraska Medical Center reported success in treating HIV infection in animals using CRISPR technology